DiaMedica Therapeutics, a Phase II biotech developing therapies for acute ischemic stoke and vascular dementia, filed on Friday with the SEC to raise up to $15 million in an initial public offering. DiaMedica is currently listed on both the OTCQB marketplace and the Toronto Stock Exchange.
The Minneapolis, MN-based company was founded in 2000 and plans to list on the Nasdaq under the symbol DMAC. DiaMedica Therapeutics filed confidentially on November 1, 2018. Craig-Hallum Capital Group is the sole bookrunner on the deal. No pricing terms were disclosed.
The article
Stroke and dementia biotech DiaMedica Therapeutics files for a $15 million IPO originally appeared on IPO investment manager Renaissance Capital's web site renaissancecapital.com.
Investment Disclosure: The information and opinions expressed herein were prepared by Renaissance Capital's research analysts and do not constitute an offer to buy or sell any security. Renaissance Capital's
Renaissance IPO ETF (symbol: IPO) ,
Renaissance International ETF (symbol: IPOS) , or separately managed institutional accounts may have investments in securities of companies mentioned.